Case report of a serious adverse event following the administration of t cells transduced with a chimeric antigen receptor recognizing ERBB2

Molecular Therapy

Volumn 18, Issue 4, 2010, Pages 843-851

  Morgan, Richard A ^a   Yang, James C ^a   Kitano, Mio ^a   Dudley, Mark E ^a   Laurencot, Carolyn M ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CHIMERIC ANTIGEN RECEPTOR; CYCLOPHOSPHAMIDE; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 6; MONOCLONAL ANTIBODY; OXALIPLATIN; RECEPTOR; RECOMBINANT INTERLEUKIN 2; RETROVIRUS VECTOR; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; CELLULAR DISTRIBUTION; COCULTURE; COLON CANCER; CYTOKINE RELEASE; DEATH; FEMALE; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; IN VITRO STUDY; INFUSION; INTUBATION; LIVER METASTASIS; LUNG ALVEOLUS EPITHELIUM; LUNG INFILTRATE; LUNG METASTASIS; NONMYELOABLATIVE CONDITIONING; PERIPHERAL LYMPHOCYTE; PROTEIN EXPRESSION; RESPIRATORY DISTRESS; T LYMPHOCYTE; THORAX RADIOGRAPHY;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; COLONIC NEOPLASMS; CYTOKINES; FATAL OUTCOME; FEMALE; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LIVER NEOPLASMS; LUNG NEOPLASMS; RECEPTOR, ERBB-2; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; RESPIRATORY DISTRESS SYNDROME, ADULT; T-LYMPHOCYTES; TRANSDUCTION, GENETIC;

EID: 77950475517     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.24     Document Type: Article

References (61)

1. Rubin, I and Yarden, Y (2001). The basic biology of HER2. Ann Oncol 12 (suppl. 1): S3-S8. (Pubitemid 32750577)
2. Yarden, Y and Shilo, BZ (2007). SnapShot: EGFR signaling pathway. Cell 131: 1018. (Pubitemid 350138094)
3. Yarden, Y and Sliwkowski, MX (2001). Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137. (Pubitemid 33674041)
4. Slamon, DJ, Godolphin, W, Jones, LA, Holt, JA, Wong, SG, Keith, DE et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712. (Pubitemid 19147683)
5. Ross, JS and McKenna, BJ (2001). The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 19: 554-568. (Pubitemid 32619394)
6. Lassus, H, Sihto, H, Leminen, A, Joensuu, H, Isola, J, Nupponen, NN et al. (2006). Gene amplifcation, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med 84: 671-681. (Pubitemid 44164262)
7. Kameda, T, Yasui, W, Yoshida, K, Tsujino, T, Nakayama, H, Ito, M et al. (1990). Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplifcation. Cancer Res 50: 8002-8009.
8. Carter, P, Presta, L, Gorman, CM, Ridgway, JB, Henner, D, Wong, WL et al. (1992). Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285-4289.
9. Buzdar, AU, Ibrahim, NK, Francis, D, Booser, DJ, Thomas, ES, Theriault, RL et al. (2005). Signifcantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23: 3676-3685. (Pubitemid 46252462)
10. Hudis, CA (2007). Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357: 39-51. (Pubitemid 47026733)
11. Disis, ML, Gooley, TA, Rinn, K, Davis, D, Piepkorn, M, Cheever, MA et al. (2002). Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 20: 2624-2632. (Pubitemid 34575634)
12. Peoples, GE, Gurney, JM, Hueman, MT, Woll, MM, Ryan, GB, Storrer, CE et al. (2005). Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 23: 7536-7545.
13. Morse, MA, Hobeika, A, Osada, T, Niedzwiecki, D, Marcom, PK, Blackwell, KL et al. (2007). Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. J Transl Med 5: 42. (Pubitemid 350020419)
14. Bernhard, H, Neudorfer, J, Gebhard, K, Conrad, H, Hermann, C, Nährig, J et al. (2008). Adoptive transfer of autologous, HER2-specifc, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunol Immunother 57: 271-280. (Pubitemid 350159915)
15. Dudley, ME, Wunderlich, JR, Yang, JC, Sherry, RM, Topalian, SL, Restifo, NP et al. (2005). Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23: 2346-2357.
16. Dudley, ME, Yang, JC, Sherry, R, Hughes, MS, Royal, R, Kammula, U et al. (2008). Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26: 5233-5239.
17. Vera, JF, Brenner, MK and Dotti, G (2009). Immunotherapy of human cancers using gene modifed T lymphocytes. Curr Gene Ther 9: 396-408.
18. Sadelain, MRI and Brentjens R (2003). Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 3: 35-45. (Pubitemid 37328885)
19. Murphy, A, Westwood, JA, Teng, MW, Moeller, M, Darcy, PK and Kershaw, MH (2005). Gene modifcation strategies to induce tumor immunity. Immunity 22: 403-414. (Pubitemid 40545107)
20. Morgan, RA, Dudley, ME, Wunderlich, JR, Hughes, MS, Yang, JC, Sherry, RM et al. (2006). Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129.
21. Johnson, LA, Morgan, RA, Dudley, ME, Cassard, L, Yang, JC, Hughes, MS et al. (2009). Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114: 535-546.
22. Eshhar, Z (2008). The T-body approach: redirecting T cells with antibody specifcity. Handb Exp Pharmacol 329-342.
23. Eshhar, Z, Waks, T, Gross, G and Schindler, DG (1993). Specifc activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 90: 720-724. (Pubitemid 23028937)
24. Pule, MA, Savoldo, B, Myers, GD, Rossig, C, Russell, HV, Dotti, G et al. (2008). Virus-specifc T cells engineered to coexpress tumor-specifc receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14: 1264-1270.
25. Kershaw, MH, Westwood, JA, Parker, LL, Wang, G, Eshhar, Z, Mavroukakis, SA et al. (2006). A phase I study on adoptive immunotherapy using gene-modifed T cells for ovarian cancer. Clin Cancer Res 12(20 Pt 1): 6106-6115. (Pubitemid 44703776)
26. Lamers, CH, Sleijfer, S, Vulto, AG, Kruit, WH, Kliffen, M, Debets, R et al. (2006). Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: frst clinical experience. J Clin Oncol 24: e20-e22.
27. Park, JR, Digiusto, DL, Slovak, M, Wright, C, Naranjo, A, Wagner, J et al. (2007). Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 15: 825-833. (Pubitemid 46432004)
28. Zhao, Y, Wang, QJ, Yang, S, Kochenderfer, JN, Zheng, Z, Zhong, X et al. (2009). A herceptin-based chimeric antigen receptor with modifed signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol 183: 5563-5574.
29. Slamon, DJ, Leyland-Jones, B, Shak, S, Fuchs, H, Paton, V, Bajamonde, A et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792. (Pubitemid 32222155)
30. Romond, EH, Perez, EA, Bryant, J, Suman, VJ, Geyer, CE Jr, Davidson, NE et al. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684. (Pubitemid 41464706)
31. Beano, A, Signorino, E, Evangelista, A, Brusa, D, Mistrangelo, M, Polimeni, MA et al. (2008). Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J Transl Med 6: 25. (Pubitemid 351803896)
32. Gennari, R, Menard, S, Fagnoni, F, Ponchio, L, Scelsi, M, Tagliabue, E et al. (2004). Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10: 5650-5655. (Pubitemid 39180938)
33. Varchetta, S, Gibelli, N, Oliviero, B, Nardini, E, Gennari, R, Gatti, G et al. (2007). Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res 67: 11991-11999.
34. Mani, A, Roda, J, Young, D, Caligiuri, MA, Fleming, GF, Kaufman, P et al. (2009). A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. Breast Cancer Res Treat 117: 83-89.
35. Parihar, R, Nadella, P, Lewis, A, Jensen, R, De Hoff, C, Dierksheide, JE et al. (2004). A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon γ production in a subset of patients. Clin Cancer Res 10: 5027-5037. (Pubitemid 39099777)
36. Fisher, B, Packard, BS, Read, EJ, Carrasquillo, JA, Carter, CS, Topalian, SL et al. (1989). Tumor localization of adoptively transferred indium-111 labeled tumor infltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol 7: 250-261. (Pubitemid 19048459)
37. Taraban, VY, Rowley, TF, O'Brien, L, Chan, HT, Haswell, LE, Green, MH et al. (2002). Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses. Eur J Immunol 32: 3617-3627. (Pubitemid 36024398)
38. Wang, C, Lin, GH, McPherson, AJ and Watts, TH (2009). Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol Rev 229: 192-215.
39. Zhong, XS, Matsushita, M, Plotkin, J, Riviere, I and Sadelain, M (2009). Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI(3) kinase/AKT/Bcl-X(L) Activation and CD8(+) T Cell-mediated Tumor Eradication. Mol Ther (epub ahead of print).
40. Milone, MC, Fish, JD, Carpenito, C, Carroll, RG, Binder, GK, Teachey, D et al. (2009). Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic effcacy in vivo. Mol Ther 17: 1453-1464.
41. Carpenito, C, Milone, MC, Hassan, R, Simonet, JC, Lakhal, M, Suhoski, MM et al. (2009). Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA 106: 3360-3365.
42. Till, BG, Jensen, MC, Wang, J, Chen, EY, Wood, BL, Greisman, HA et al. (2008). Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modifed autologous CD20-specifc T cells. Blood 112: 2261-2271.
43. Scheving, LA, Zhang, L, Stevenson, MC, Kwak, ES and Russell, WE (2006). The emergence of ErbB2 expression in cultured rat hepatocytes correlates with enhanced and diversifed EGF-mediated signaling. Am J Physiol Gastrointest Liver Physiol 291: G16-G25. (Pubitemid 44024658)
44. Lenz, A, Franklin, GA and Cheadle, WG (2007). Systemic infammation after trauma. Injury 38: 1336-1345.
45. Wang, H and Ma, S (2008). The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. Am J Emerg Med 26: 711-715. (Pubitemid 351905818)
46. Chatenoud L, Ferran C, Legendre C, Thouard I, Merite S, Reuter A et al. (1990). In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 49: 697-702. (Pubitemid 20146948)
47. Sgro, C (1995). Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review. Toxicology 105: 23-29. (Pubitemid 126738973)
48. Stebbings, R, Findlay, L, Edwards, C, Eastwood, D, Bird, C, North, D et al. (2007). "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol 179: 3325-3331.
49. Stebbings, R, Poole, S and Thorpe, R (2009). Safety of biologics, lessons learnt from TGN1412. Curr Opin Biotechnol 20: 673-677.
50. Suntharalingam, G, Perry, MR, Ward, S, Brett, SJ, Castello-Cortes, A, Brunner, MD et al. (2006). Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355: 1018-1028. (Pubitemid 44343545)
51. Weiner, LM, Clark, JI, Davey, M, Li, WS, Garcia de Palazzo, I, Ring, DB et al. (1995). Phase I trial of 2B1, a bispecifc monoclonal antibody targeting c-erbB-2 and Fcγ RIII. Cancer Res 55: 4586-4593.
52. Akalin, E and Murphy, B (2001). Gene polymorphisms and transplantation. Curr Opin Immunol 13: 572-576. (Pubitemid 32817036)
53. Girnita, DM, Webber, SA and Zeevi, A (2008). Clinical impact of cytokine and growth factor genetic polymorphisms in thoracic organ transplantation. Clin Lab Med 28: 423-40, vi.
54. Marshall, SE and Welsh, KI (2001). The role of cytokine polymorphisms in rejection after solid organ transplantation. Genes Immun 2: 297-303. (Pubitemid 33674240)
55. Tischendorf, JJ, Yagmur, E, Scholten, D, Vidacek, D, Koch, A, Winograd, R et al. (2007). The interleukin-6 (IL6)-174 G/C promoter genotype is associated with the presence of septic shock and the ex vivo secretion of IL6. Int J Immunogenet 34: 413-418. (Pubitemid 350126010)
56. Stanilova, SA, Miteva, LD, Karakolev, ZT and Stefanov, CS (2006). Interleukin-10-1082 promoter polymorphism in association with cytokine production and sepsis susceptibility. Intensive Care Med 32: 260-266. (Pubitemid 43251147)
57. Cope, D (2004). Tumor lysis syndrome. Clin J Oncol Nurs 8: 415-416.
58. Cohen, CJ, Zheng, Z, Bray, R, Zhao, Y, Sherman, LA, Rosenberg, SA et al. (2005). Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. J Immunol 175: 5799-5808. (Pubitemid 41508064)
59. Theoret, MR, Cohen, CJ, Nahvi, AV, Ngo, LT, Suri, KB, Powell, DJ Jr et al. (2008). Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells. Hum Gene Ther 19: 1219-1232.
60. Press, MF, Cordon-Cardo, C and Slamon, DJ (1990). Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5: 953-962. (Pubitemid 20220236)
61. Lotem, M, Zhao, Y, Riley, J, Hwu, P, Morgan, RA, Rosenberg, SA et al. (2006). Presentation of tumor antigens by dendritic cells genetically modifed with viral and nonviral vectors. J Immunother 29: 616-627. (Pubitemid 44674045)